复方蟾酥注射液用于胃癌患者术后化疗的临床研究

doi:10.3969/j.issn.1671-7171.2017.02.012

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate clinical effect of the injectable compound venom recipe on the immune function of gastric carcinoma patients underwent postoperative chemotherapy. 【Methods】The patients (84 cases) with gastric cancer were randomly divided into control group and observation group according to the age, gender, tumor location and pathological stage of patients. The control group were treated by 12 course of chemotherapy program FOLFOX4; the patients in observation group were additionally implemented the treatment with the injectable compound venom recipe during FOLFOX4 chemotherapy therapy. It's compared that the change of immune indicators before and after chemotherapy and the improvement of patients' life quality, the incidence of adverse reaction during the process of chemotherapy . 【Results】 In the immune indicator detection experiments before and after chemotherapy, we observed that the patients in observation group possessed significantly higher levels of peripheral blood immunoglobulin (IgG, IgA, IgM) and complement components (C3 and C4) than those of the control group (P<0.05), and the number and proportion of CD4⁺ T cells in peripheral blood of patients in the observation group were significantly higher than that of the control group (P<0.05). KPS score of quality of life after chemotherapy proved that the scores of observation group patients was significantly higher than that of the control patients, while the effectiveness of chemotherapy in observation group was also significantly higher than that in the control group (P<0.05). Comparing with control group, the incidence of adverse reaction as diarrhea, infection, thrombocytopenia, leukopenia, lower hemoglobin, the decrease of glutamic-oxalacetic transaminase and glutamic-pyruvic transaminase were significantly lower than those in the control group (P<0.05); Whereas, the incidence of adverse reaction as anorexia, hair loss, nausea, vomiting, arrhythmia, creatinine elevation, urea nitrogen increase, total bilirubin increase and pain, had no significant difference between the control and the observation group (P>0.05). 【Conclusion】The useage of injectable compound venom recipe can significantly improve immune function and life quality during postoperative chemotherapy for patients with gastric cancer, and reduce the side reaction of chemotherapy, which is worthy of clinical application.

Key words： INJECTIO VENENUM BUFONIS/TU Stomach Neoplasms/SU Stomach Neoplasms/DT Quality of Life

Received: 05 December 2016

PACS:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Jia-yu
	ZHANG Yong

Cite this article:

LU Jia-yu,ZHANG Yong. Clinical research on Injectable Compound Venom Recipe Using in Postoperative Chemotherapy of Gastric Carcinoma Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(2): 243-282.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.02.012 OR http://www.jcr.net.cn/EN/Y2017/V34/I2/243

[1] 邹小农, 孙喜斌, 陈万青, 等. 2003~2007年中国胃癌发病与死亡情况分析[J].肿瘤, 2012, 32 (2): 109-114.
[2] 邹文斌, 李兆申. 中国胃癌发病率及死亡率研究进展[J].中国实用内科杂志, 2014, 34 (4): 408-415.
[3] 张国伟, 宋丽杰. 进展期胃癌化疗现状与进展 [J].临床药物治疗杂志, 2009, 7 (5): 14-18.
[4] 秦叔逵, 龚新雷. 晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志, 2006, 11 (9): 641-652.
[5] 岳素荣,贺吉香. 蟾酥研究进展[J].辽宁中医药大学学报,2015,(11):222-224.
[6] 寇冠军,秦姿凡,邓雅芳,等. 蟾酥的研究进展[J].中草药,2014,(21):3185-3189.
[7] Christian W. The development of the TNM classification of gastric cancer [J].Pathol Int,2015, 65(8):
[8] 文新元, 黄文峰, 等. 分析不同部位的胃癌肿瘤术式选择与预后 [J].中华普外科手术学杂志(电子版), 2014, 8 (3): 256-259.
[9] 胡祥. 胃癌根治术式选择与原则[J].中华普外科手术学杂志(电子版), 2013, 7(1):4-9.
[10] Wang X,Wang YS.Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen) [J].Med Oncol,2011, 28 (1): 274-279.
[11] 吴芳,张弘纲,冉飞武,等.FOLFOX4 方案和DP(O)F方案一线治疗晚期胃癌的疗效分析[J].癌症,2008, 27 (4): 413-417.
[12] 滕晓弘, 刘威. 蟾酥注射液治疗晚期恶性肿瘤临床观察[J].中国医药指南, 2008, 6 (1): 57-58.
[13] Schaafsma J, Osoba D. The Karnofsky performance status scale re-examined: a cross-validation with the EORTC-C30 [J].Quality of Life Research,1994, 3 (6): 413-424.
[14] 段庚仙. 恶性肿瘤化疗的毒副作用及其防治[J].肿瘤研究与临床, 2004, 16 (5): 353-354.
[15] 于洋,安娜,王小亮,等. 蟾酥注射液对小鼠免疫细胞影响的实验研究[J].中国农学通报,2009,(22):1-6.
[16] 高欣,董瑞华.蟾酥注射液联合化疗治疗晚期非小细胞肺癌的meta分析[J].肿瘤药学, 2013, 3 (6): 467-470.
[17] 刘俊珊,张冬梅.蟾酥及其活性成分抗肿瘤作用研究进展 [J].国际药学研究杂志, 2009, 36 (2): 115-120.
[18] 张洲姬,杨云柯. 蟾酥制剂辅助治疗肿瘤的疗效及安全性系统综述和Meta分析[J].上海中医药大学学报,2013,(05):35-40.